Development and validation of a host-dependent, PDL1-independent, biomarker to predict 6-month progression-free survival in metastatic non-small cell lung cancer (mNSCLC) patients treated with anti-PD1 immune checkpoint inhibitors (ICI) in the CERTIM Cohort: The ELY study-Reference-Cited by-同舟云学术

Development and validation of a host-dependent, PDL1-independent, biomarker to predict 6-month progression-free survival in metastatic non-small cell lung cancer (mNSCLC) patients treated with anti-PD1 immune checkpoint inhibitors (ICI) in the CERTIM Cohort: The ELY study

Published:2021-11 Issue: Volume:73 Page:103630
ISSN:2352-3964
Container-title:EBioMedicine
language:en
Short-container-title:EBioMedicine

Author:

Boudou-Rouquette Pascaline^ORCID,Arrondeau Jennifer,Gervais Claire,Durand Jean-Philippe,Fabre Elizabeth,De Percin Sixtine,Villeminey Clémentine Vaquin,Piketty Anne-Catherine,Rassy Nathalie,Ulmann Guillaume^ORCID,Damotte Diane,Mansuet-Lupo Audrey,Giraud Frédérique,Alifano Marco,Wislez Marie,Alexandre Jérôme,Jouinot Anne,Goldwasser François

Funder

Baxter International

Publisher

Elsevier BV

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Reference28 articles.

1. Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis;Antonia;Lancet Oncol,2019

2. Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer;Hellmann;N Engl J Med,2019

3. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer;Reck;N Engl J Med,2016

4. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors;Routy;Science,2018

5. Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer;Derosa;Ann Oncol,2018

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Routine assessment of nutritional, functional and inflammatory criteria in patients with cancer: A systematic review;Clinical Nutrition ESPEN;2024-10

2. A comprehensive supportive care program for fine-tuning cancer immunotherapy;Supportive Care in Cancer;2024-06-22

3. Extending the dosing intervals of nivolumab: model-based simulations in unselected cancer patients;British Journal of Cancer;2024-03-26

4. Influence of cachexia on immunotherapy efficacy and prognosis for malignant tumors of digestive system;2023-08-04

5. Prognostic score and sex-specific nomograms to predict survival in resectable lung cancer: a French nationwide study from the Epithor cohort database;The Lancet Regional Health - Europe;2023-03